MIAMI BEACH — There are a lot of appetizing data being served this week at the Transcatheter Cardiovascular Thereapeutics (TCT) meeting in Miami, but one of the main courses is clearly transcatheter aortic valve implant (TAVI), also known as transcatheter aortic valve replacement (TAVR). TCT, sponsored by the Cardiovascular Research Foundation (New York), dedicated a sizeable portion of the meeting to the current data on TAVI/TAVR featuring Edwards Lifesciences (Irvine, California) at the head of the table with its Sapien valve, with several other companies wrestling for a slice of the TAVI pie.